Not Yet RecruitingNot Applicable

AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)

1,170 participantsStarted 2026-05-18

Plain-language summary

This study aims to prospectively validate a retrospective cohort-derived AI-based multimodal model and explore tumor heterogeneity and the immune microenvironment to guide TACE combined with immunotherapy and targeted therapy in HCC.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

. Prospective Study Cohort 2.1 Inclusion Criteria Age ≥18 years; Patients with hepatocellular carcinoma confirmed by histopathology or clinical diagnosis; Scheduled to receive first-line TACE combined with immunotherapy and targeted therapy; At least one intrahepatic lesion that is repeatedly measurable according to RECIST v1.1; Expected survival of more than 3 months. 2.2 Exclusion Criteria Known sarcomatoid hepatocellular carcinoma or fibrolamellar hepatocellular carcinoma; Presence of other active malignancies within the past 5 years or concurrent active malignancies other than hepatocellular carcinoma; Other factors that, in the investigator's judgment, make the patient unsuitable for participation in this study; Severe allergy to iodinated contrast agents that preclude imaging examinations or TACE treatment.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Prediction Performance of the AI Model

Timeframe: From enrollment to approximately 2 years

Trial details

NCT IDNCT07584317

SponsorGao-jun Teng

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2027-05-31

Contact for this trial

Zhicheng Jin, MD

+86-025-83272121 jinzhic@foxmail.com

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials